PRAXIS PRECISION MEDICINES, INC. Financing Cash Flow
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Financing Cash Flow of $614.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.57M, a 84.03% decline year-over-year.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $609.43M, a 1022.98% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $612.52M, a 438.40% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $6.76M, a 370.47% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for fiscal 2025 was $702.17M, a 36.52% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for fiscal 2024 was $514.32M, a 459.83% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for fiscal 2023 was $91.87M, a 777.89% increase from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. net cash provided by (used in) financing activities for fiscal 2022 was $10.46M, a 90.27% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $614.00M 10-Q · filed 2026-08-06 | $1.23B derived: sum of 3 quarters · filed 2026-08-06 | $1.23B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $609.43M 10-Q · filed 2026-05-07 | $1.22B derived: sum of 2 quarters · filed 2026-05-07 | $1.23B derived: sum of 3 quarters · filed 2026-05-07 | $1.26B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $612.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $619.27M derived: sum of 2 quarters · filed 2026-02-19 | $647.90M derived: sum of 3 quarters · filed 2026-08-06 | $702.17M 10-K · filed 2026-02-19 |
| 2025-09-30 | $6.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $35.39M derived: sum of 2 quarters · filed 2026-08-06 | $89.66M 10-Q · filed 2025-11-05 | $203.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $28.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $82.90M 10-Q · filed 2026-08-06 | $196.67M derived: sum of 3 quarters · filed 2026-08-06 | $198.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $54.27M 10-Q · filed 2026-05-07 | $168.04M derived: sum of 2 quarters · filed 2026-05-07 | $169.47M derived: sum of 3 quarters · filed 2026-05-07 | $385.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $113.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $115.20M derived: sum of 2 quarters · filed 2026-02-19 | $331.57M derived: sum of 3 quarters · filed 2026-02-19 | $514.32M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $217.80M derived: sum of 2 quarters · filed 2025-11-05 | $400.56M 10-Q · filed 2025-11-05 | $404.68M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $216.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $399.12M 10-Q · filed 2025-08-04 | $403.25M derived: sum of 3 quarters · filed 2026-02-19 | $403.25M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $182.76M 10-Q · filed 2025-05-02 | $186.88M derived: sum of 2 quarters · filed 2026-02-19 | $186.88M derived: sum of 3 quarters · filed 2026-02-19 | $256.56M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.13M derived: sum of 2 quarters · filed 2026-02-19 | $73.80M derived: sum of 3 quarters · filed 2026-02-19 | $91.87M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $69.67M derived: sum of 2 quarters · filed 2024-11-06 | $87.75M 10-Q · filed 2024-11-06 | $93.13M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $69.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $87.75M 10-Q · filed 2024-08-13 | $93.13M derived: sum of 3 quarters · filed 2024-08-13 | $96.50M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $18.07M 10-Q · filed 2024-05-13 | $23.46M derived: sum of 2 quarters · filed 2024-05-13 | $26.82M derived: sum of 3 quarters · filed 2024-05-13 | $27.33M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $8.75M derived: sum of 2 quarters · filed 2024-03-05 | $9.26M derived: sum of 3 quarters · filed 2024-03-05 | $10.46M 10-K · filed 2024-03-05 |
| 2022-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.87M derived: sum of 2 quarters · filed 2023-11-07 | $5.08M 10-Q · filed 2023-11-07 | $12.79M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $504.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.71M 10-Q · filed 2023-08-09 | $9.43M derived: sum of 3 quarters · filed 2023-08-09 | $9.64M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.21M 10-Q · filed 2023-05-11 | $8.92M derived: sum of 2 quarters · filed 2023-05-11 | $9.13M derived: sum of 3 quarters · filed 2023-05-11 | $108.52M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $7.92M derived: sum of 2 quarters · filed 2023-02-07 | $107.31M derived: sum of 3 quarters · filed 2023-02-07 | $107.59M 10-K · filed 2023-02-07 |
| 2021-09-30 | $212.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $99.60M derived: sum of 2 quarters · filed 2022-11-09 | $99.87M 10-Q · filed 2022-11-09 | $301.94M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $99.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $99.66M 10-Q · filed 2022-08-08 | $301.73M derived: sum of 3 quarters · filed 2022-08-08 | $410.63M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $276.00K 10-Q · filed 2022-05-09 | $202.34M derived: sum of 2 quarters · filed 2022-05-09 | $311.25M derived: sum of 3 quarters · filed 2022-05-09 | $334.69M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $202.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $310.97M derived: sum of 2 quarters · filed 2022-02-28 | $334.42M derived: sum of 3 quarters · filed 2022-02-28 | $304.42M 10-K · filed 2022-02-28 |
| 2020-09-30 | $108.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $132.35M derived: sum of 2 quarters · filed 2021-11-03 | $102.35M 10-Q · filed 2021-11-03 | $152.80M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $23.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$6.55M 10-Q · filed 2021-08-16 | $43.90M derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | -$30.00M 10-Q · filed 2021-05-11 | $20.45M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $50.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $60.39M 10-K · filed 2021-03-17 | ||
| 2019-09-30 | $9.94M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |